Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-02-23

AUTHORS

Sayaka Namba, Minako Yamaoka-Tojo, Ryota Kakizaki, Teruyoshi Nemoto, Kazuhiro Fujiyoshi, Takehiro Hashikata, Lisa Kitasato, Takuya Hashimoto, Ryo Kameda, Kentaro Meguro, Takao Shimohama, Taiki Tojo, Junya Ako

ABSTRACT

In recent years, direct oral anticoagulants (DOACs) of dabigatran, rivaroxaban, apixaban, edoxaban, which are all alternatives to warfarin, have been released. The use of DOACs is becoming more widespread in the clinical management of thrombotic stroke risk in patients with atrial fibrillation (AF). In large-scale clinical trials of each drug, DOACs were reported to inhibit intracranial hemorrhage, stroke, and death compared to warfarin. Warfarin is an endogenous vitamin K antagonist; therefore, patients who are taking warfarin must be prohibited from taking vitamin K. Vitamin K is an essential cofactor required for the ɤ-carboxylation of vitamin K-dependent proteins including coagulation factors, osteocalcin (OC), matrix Gla protein (MGP), and the growth arrest-specific 6 (GAS6). OC is a key factor for bone matrix formation. MGP is a local inhibitor of soft tissue calcification in the vessel wall. GAS6 prevents the apoptosis of vascular smooth muscle cells. Therefore, decrease of blood vitamin K levels may cause osteoporosis, vascular calcification, and the inhibition of vessels angiogenesis. This study aimed to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction. We studied 21 consecutive patients with persistent or chronic AF, who were treated with warfarin at least for 12 months. Warfarin administration was changed to rivaroxaban (10 or 15 mg/day) in all patients. Osteopontin (OPN), bone alkaline phosphatase (BAP), and under-carboxylated osteocalcin (ucOC) were measured. Pulse wave velocity (PWV) and augmentation index (AI) were also measured as atherosclerosis assessments. All measurements were done before and six months after the rivaroxaban treatment. There was a significant increase in serum level of BAP compared to baseline (12.5 ± 4.6 to 13.4 ± 4.1 U/L, P < 0.01). In contrast, there was a significant decrease in the serum level of ucOC (9.5 ± 5.0 to 2.7 ± 1.3 ng/ml, P < 0.01). Also, in the ucOC levels, there was a significant negative correlation between baseline values and baseline to 6-months changes in high ucOC group (r = −0.97, P < 0.01). The atherosclerosis- and osteoporosis-related biomarker, serum level of OPN were significantly decreased compared to baseline (268.3 ± 46.8 to 253.4 ± 47.1 ng/ml, P < 0.01). AI and PWV were significantly decreased after 6 months of treatment with rivaroxaban (33.9 ± 18.4 to 24.7 ± 18.4%, P = 0.04; 1638.8 ± 223.0 to 1613.0 ± 250.1 m/s, P = 0.03, respectively). Switching to rivaroxaban from warfarin in patients with atrial fibrillation was associated with an increase of bone formation markers and a decrease of bone resorption markers, and also improvements of PWV and AI. More... »

PAGES

977-982

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-017-0950-2

DOI

http://dx.doi.org/10.1007/s00380-017-0950-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083862484

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28233091


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone and Bones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Substitution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Factor Xa Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intracranial Thrombosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pulse Wave Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rivaroxaban", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Stiffness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Namba", 
        "givenName": "Sayaka", 
        "id": "sg:person.01342560525.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342560525.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, 252-0373, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, 252-0373, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamaoka-Tojo", 
        "givenName": "Minako", 
        "id": "sg:person.0630073565.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630073565.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kakizaki", 
        "givenName": "Ryota", 
        "id": "sg:person.010156707735.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010156707735.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nemoto", 
        "givenName": "Teruyoshi", 
        "id": "sg:person.010754270335.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010754270335.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujiyoshi", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.01222621771.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222621771.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashikata", 
        "givenName": "Takehiro", 
        "id": "sg:person.0641672710.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641672710.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kitasato", 
        "givenName": "Lisa", 
        "id": "sg:person.01023151240.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023151240.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashimoto", 
        "givenName": "Takuya", 
        "id": "sg:person.01105601162.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105601162.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kameda", 
        "givenName": "Ryo", 
        "id": "sg:person.01002676641.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002676641.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meguro", 
        "givenName": "Kentaro", 
        "id": "sg:person.016506421751.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016506421751.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimohama", 
        "givenName": "Takao", 
        "id": "sg:person.01116550365.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116550365.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tojo", 
        "givenName": "Taiki", 
        "id": "sg:person.01220560516.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220560516.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ako", 
        "givenName": "Junya", 
        "id": "sg:person.0744472011.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744472011.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00774-009-0094-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017555813", 
          "https://doi.org/10.1007/s00774-009-0094-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2119/molmed.2009.00052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068965203", 
          "https://doi.org/10.2119/molmed.2009.00052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ijir.2014.14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025583726", 
          "https://doi.org/10.1038/ijir.2014.14"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-016-0868-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004414565", 
          "https://doi.org/10.1007/s00380-016-0868-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3348-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008902979", 
          "https://doi.org/10.1007/s00125-014-3348-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-014-0496-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043676979", 
          "https://doi.org/10.1007/s00380-014-0496-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00774-013-0490-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004167978", 
          "https://doi.org/10.1007/s00774-013-0490-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02-23", 
    "datePublishedReg": "2017-02-23", 
    "description": "In recent years, direct oral\u00a0anticoagulants (DOACs) of dabigatran, rivaroxaban, apixaban, edoxaban, which are all alternatives to warfarin, have been released. The use of DOACs is becoming more widespread in the clinical management of thrombotic stroke risk in patients with atrial fibrillation (AF). In large-scale clinical trials of each drug, DOACs were reported to inhibit intracranial hemorrhage, stroke, and death compared to warfarin. Warfarin is an endogenous vitamin K antagonist; therefore, patients who are taking warfarin must be prohibited from taking vitamin K. Vitamin K is an essential cofactor required for the \u0264-carboxylation of vitamin K-dependent proteins including coagulation factors, osteocalcin (OC), matrix Gla protein (MGP), and the growth arrest-specific 6 (GAS6). OC is a key factor for bone matrix formation. MGP is a local inhibitor of soft tissue calcification in the vessel wall. GAS6 prevents the apoptosis of vascular smooth muscle cells. Therefore, decrease of blood vitamin K levels may cause osteoporosis, vascular calcification, and the inhibition of vessels angiogenesis. This study aimed to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction. We studied 21 consecutive patients with persistent or chronic AF, who were treated with warfarin at least for 12 months. Warfarin administration was changed to rivaroxaban (10 or 15\u00a0mg/day) in all patients. Osteopontin (OPN), bone alkaline phosphatase (BAP), and under-carboxylated osteocalcin (ucOC) were measured. Pulse wave velocity (PWV) and augmentation index (AI) were also measured as atherosclerosis assessments. All measurements were done before and six months after the rivaroxaban treatment. There was a significant increase in serum level of BAP compared to baseline (12.5\u2009\u00b1\u20094.6 to 13.4\u2009\u00b1\u20094.1\u00a0U/L, P\u2009<\u20090.01). In contrast, there was a significant decrease in the serum level of ucOC (9.5\u2009\u00b1\u20095.0 to 2.7\u2009\u00b1\u20091.3\u00a0ng/ml, P\u2009<\u20090.01). Also, in the ucOC levels, there was a significant negative correlation between baseline values and baseline to 6-months changes in high ucOC group (r\u2009=\u2009\u22120.97, P\u2009<\u20090.01). The atherosclerosis- and osteoporosis-related biomarker, serum level of OPN were significantly decreased compared to baseline (268.3\u2009\u00b1\u200946.8 to 253.4\u2009\u00b1\u200947.1\u00a0ng/ml, P\u2009<\u20090.01). AI and PWV were significantly decreased after 6\u00a0months of treatment with rivaroxaban (33.9\u2009\u00b1\u200918.4 to 24.7\u2009\u00b1\u200918.4%, P\u2009=\u20090.04; 1638.8\u2009\u00b1\u2009223.0 to 1613.0\u2009\u00b1\u2009250.1\u00a0m/s, P\u2009=\u20090.03, respectively). Switching to rivaroxaban from warfarin in patients with atrial fibrillation was associated with an\u00a0increase\u00a0of bone formation markers and a\u00a0decrease\u00a0of bone resorption markers, and also improvements of PWV\u00a0and AI.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-017-0950-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "keywords": [
      "pulse wave velocity", 
      "bone alkaline phosphatase", 
      "matrix Gla protein", 
      "atrial fibrillation", 
      "augmentation index", 
      "serum levels", 
      "vascular calcification", 
      "improvement of PWV", 
      "vitamin K. Vitamin K", 
      "vitamin K", 
      "large-scale clinical trials", 
      "use of DOACs", 
      "vitamin K antagonists", 
      "vascular endothelial dysfunction", 
      "bone metabolism markers", 
      "vitamin K levels", 
      "chronic atrial fibrillation", 
      "months of treatment", 
      "bone resorption markers", 
      "bone mineral metabolism", 
      "bone formation markers", 
      "vascular smooth muscle cells", 
      "soft tissue calcification", 
      "smooth muscle cells", 
      "carboxylated osteocalcin", 
      "K antagonists", 
      "rivaroxaban treatment", 
      "stroke risk", 
      "endothelial dysfunction", 
      "consecutive patients", 
      "resorption markers", 
      "metabolism markers", 
      "arterial stiffness", 
      "intracranial hemorrhage", 
      "warfarin administration", 
      "formation markers", 
      "ucOC levels", 
      "clinical management", 
      "clinical trials", 
      "mineral metabolism", 
      "rivaroxaban", 
      "atherosclerosis assessment", 
      "baseline values", 
      "coagulation factors", 
      "patients", 
      "warfarin", 
      "tissue calcification", 
      "vessel angiogenesis", 
      "significant negative correlation", 
      "Gla protein", 
      "muscle cells", 
      "bone matrix formation", 
      "fibrillation", 
      "local inhibitor", 
      "significant decrease", 
      "vessel wall", 
      "calcification", 
      "baseline", 
      "months", 
      "osteocalcin", 
      "significant increase", 
      "alkaline phosphatase", 
      "osteopontin", 
      "markers", 
      "dependent proteins", 
      "treatment", 
      "negative correlation", 
      "DOACs", 
      "dabigatran", 
      "edoxaban", 
      "DOAC", 
      "essential cofactor", 
      "apixaban", 
      "matrix formation", 
      "ucOC", 
      "hemorrhage", 
      "levels", 
      "atherosclerosis", 
      "anticoagulants", 
      "osteoporosis", 
      "dysfunction", 
      "antagonist", 
      "stroke", 
      "wave velocity", 
      "Gas6", 
      "decrease", 
      "administration", 
      "trials", 
      "biomarkers", 
      "drugs", 
      "angiogenesis", 
      "death", 
      "factors", 
      "risk", 
      "apoptosis", 
      "inhibitors", 
      "protein", 
      "inhibition", 
      "metabolism", 
      "increase", 
      "effect", 
      "cells", 
      "group", 
      "K levels", 
      "years", 
      "assessment", 
      "phosphatase", 
      "index", 
      "management", 
      "study", 
      "contrast", 
      "correlation", 
      "improvement", 
      "recent years", 
      "changes", 
      "use", 
      "key factors", 
      "cofactor", 
      "wall", 
      "alternative", 
      "stiffness", 
      "growth", 
      "values", 
      "measurements", 
      "formation", 
      "carboxylation", 
      "velocity"
    ], 
    "name": "Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation", 
    "pagination": "977-982", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083862484"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-017-0950-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28233091"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-017-0950-2", 
      "https://app.dimensions.ai/details/publication/pub.1083862484"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_750.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-017-0950-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0950-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0950-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0950-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0950-2'


 

This table displays all metadata directly associated to this object as RDF triples.

398 TRIPLES      21 PREDICATES      183 URIs      167 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-017-0950-2 schema:about N0347f0fb548d4dcdb49f322219b21ec3
2 N0e1c56f7324b4c79b616fa27676dcc16
3 N12a0cc2f16064667af9fcca88232e5ca
4 N15601c5d97ef47a7bde5325ffeedcff7
5 N1676458b4c574d75937a012a1813546b
6 N17acec2d48264131a26dd8435de0c052
7 N1d6e9fb26e80452bab23cbeb39a0c51d
8 N29e9df9b2bae44fc8578e1e331e62523
9 N5536a71fcdd3419e921e1d0b756ebdd4
10 N84a32854a8664118a15fb7fa9c519892
11 N9a36bb4927854717919243a30b498b3b
12 Na477a870e93a44db9228ca513f393e53
13 Na59b53eaa21142c48e58df9917af43cb
14 Nb184f93b6a1b4aae9cfec8a0e524acf0
15 Nb1dd233a943647f9b96b13b88ab060ae
16 Nb9c9303af26e49a3b326f0dca5d145ac
17 Nbe962c7d3ce0441f8050053955da8b1b
18 Nd358d829bf434d29a2c502566b7b8839
19 Nd47fffd662dd40bbbe8c5eaa700fb15c
20 Nd94a91a6dca443cc9a1521f9ccfdb4be
21 Nd96d6881d3ce4f63b681805102863da5
22 Nd998f491af5546f0931bceeda2e67e55
23 Ne85b54e5565e4cc3a613db930e1c4192
24 anzsrc-for:11
25 anzsrc-for:1102
26 anzsrc-for:1103
27 schema:author Nc23e4b0aee6040c490490ce64a0bb372
28 schema:citation sg:pub.10.1007/s00125-014-3348-z
29 sg:pub.10.1007/s00380-014-0496-5
30 sg:pub.10.1007/s00380-016-0868-0
31 sg:pub.10.1007/s00774-009-0094-2
32 sg:pub.10.1007/s00774-013-0490-5
33 sg:pub.10.1038/ijir.2014.14
34 sg:pub.10.2119/molmed.2009.00052
35 schema:datePublished 2017-02-23
36 schema:datePublishedReg 2017-02-23
37 schema:description In recent years, direct oral anticoagulants (DOACs) of dabigatran, rivaroxaban, apixaban, edoxaban, which are all alternatives to warfarin, have been released. The use of DOACs is becoming more widespread in the clinical management of thrombotic stroke risk in patients with atrial fibrillation (AF). In large-scale clinical trials of each drug, DOACs were reported to inhibit intracranial hemorrhage, stroke, and death compared to warfarin. Warfarin is an endogenous vitamin K antagonist; therefore, patients who are taking warfarin must be prohibited from taking vitamin K. Vitamin K is an essential cofactor required for the ɤ-carboxylation of vitamin K-dependent proteins including coagulation factors, osteocalcin (OC), matrix Gla protein (MGP), and the growth arrest-specific 6 (GAS6). OC is a key factor for bone matrix formation. MGP is a local inhibitor of soft tissue calcification in the vessel wall. GAS6 prevents the apoptosis of vascular smooth muscle cells. Therefore, decrease of blood vitamin K levels may cause osteoporosis, vascular calcification, and the inhibition of vessels angiogenesis. This study aimed to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction. We studied 21 consecutive patients with persistent or chronic AF, who were treated with warfarin at least for 12 months. Warfarin administration was changed to rivaroxaban (10 or 15 mg/day) in all patients. Osteopontin (OPN), bone alkaline phosphatase (BAP), and under-carboxylated osteocalcin (ucOC) were measured. Pulse wave velocity (PWV) and augmentation index (AI) were also measured as atherosclerosis assessments. All measurements were done before and six months after the rivaroxaban treatment. There was a significant increase in serum level of BAP compared to baseline (12.5 ± 4.6 to 13.4 ± 4.1 U/L, P < 0.01). In contrast, there was a significant decrease in the serum level of ucOC (9.5 ± 5.0 to 2.7 ± 1.3 ng/ml, P < 0.01). Also, in the ucOC levels, there was a significant negative correlation between baseline values and baseline to 6-months changes in high ucOC group (r = −0.97, P < 0.01). The atherosclerosis- and osteoporosis-related biomarker, serum level of OPN were significantly decreased compared to baseline (268.3 ± 46.8 to 253.4 ± 47.1 ng/ml, P < 0.01). AI and PWV were significantly decreased after 6 months of treatment with rivaroxaban (33.9 ± 18.4 to 24.7 ± 18.4%, P = 0.04; 1638.8 ± 223.0 to 1613.0 ± 250.1 m/s, P = 0.03, respectively). Switching to rivaroxaban from warfarin in patients with atrial fibrillation was associated with an increase of bone formation markers and a decrease of bone resorption markers, and also improvements of PWV and AI.
38 schema:genre article
39 schema:isAccessibleForFree false
40 schema:isPartOf N6d983daebffd4fb1bd5db8dfeb633e3f
41 N91de79e4cf1e409e92933f5dacfc1ce9
42 sg:journal.1095887
43 schema:keywords DOAC
44 DOACs
45 Gas6
46 Gla protein
47 K antagonists
48 K levels
49 administration
50 alkaline phosphatase
51 alternative
52 angiogenesis
53 antagonist
54 anticoagulants
55 apixaban
56 apoptosis
57 arterial stiffness
58 assessment
59 atherosclerosis
60 atherosclerosis assessment
61 atrial fibrillation
62 augmentation index
63 baseline
64 baseline values
65 biomarkers
66 bone alkaline phosphatase
67 bone formation markers
68 bone matrix formation
69 bone metabolism markers
70 bone mineral metabolism
71 bone resorption markers
72 calcification
73 carboxylated osteocalcin
74 carboxylation
75 cells
76 changes
77 chronic atrial fibrillation
78 clinical management
79 clinical trials
80 coagulation factors
81 cofactor
82 consecutive patients
83 contrast
84 correlation
85 dabigatran
86 death
87 decrease
88 dependent proteins
89 drugs
90 dysfunction
91 edoxaban
92 effect
93 endothelial dysfunction
94 essential cofactor
95 factors
96 fibrillation
97 formation
98 formation markers
99 group
100 growth
101 hemorrhage
102 improvement
103 improvement of PWV
104 increase
105 index
106 inhibition
107 inhibitors
108 intracranial hemorrhage
109 key factors
110 large-scale clinical trials
111 levels
112 local inhibitor
113 management
114 markers
115 matrix Gla protein
116 matrix formation
117 measurements
118 metabolism
119 metabolism markers
120 mineral metabolism
121 months
122 months of treatment
123 muscle cells
124 negative correlation
125 osteocalcin
126 osteopontin
127 osteoporosis
128 patients
129 phosphatase
130 protein
131 pulse wave velocity
132 recent years
133 resorption markers
134 risk
135 rivaroxaban
136 rivaroxaban treatment
137 serum levels
138 significant decrease
139 significant increase
140 significant negative correlation
141 smooth muscle cells
142 soft tissue calcification
143 stiffness
144 stroke
145 stroke risk
146 study
147 tissue calcification
148 treatment
149 trials
150 ucOC
151 ucOC levels
152 use
153 use of DOACs
154 values
155 vascular calcification
156 vascular endothelial dysfunction
157 vascular smooth muscle cells
158 velocity
159 vessel angiogenesis
160 vessel wall
161 vitamin K
162 vitamin K antagonists
163 vitamin K levels
164 vitamin K. Vitamin K
165 wall
166 warfarin
167 warfarin administration
168 wave velocity
169 years
170 schema:name Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation
171 schema:pagination 977-982
172 schema:productId N67ba1974a6634a4695f2e878945ffff0
173 Ne0f383703b1c42c3a007d89cab3374a5
174 Ne89acbf0cf5d40a5979cee56465ce75c
175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083862484
176 https://doi.org/10.1007/s00380-017-0950-2
177 schema:sdDatePublished 2022-09-02T16:01
178 schema:sdLicense https://scigraph.springernature.com/explorer/license/
179 schema:sdPublisher N9f84146413fe4f90af409b601934b852
180 schema:url https://doi.org/10.1007/s00380-017-0950-2
181 sgo:license sg:explorer/license/
182 sgo:sdDataset articles
183 rdf:type schema:ScholarlyArticle
184 N0347f0fb548d4dcdb49f322219b21ec3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Male
186 rdf:type schema:DefinedTerm
187 N0e1c56f7324b4c79b616fa27676dcc16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Intracranial Thrombosis
189 rdf:type schema:DefinedTerm
190 N10909f4d2ca245fca1c768a49abbafea rdf:first sg:person.0630073565.16
191 rdf:rest N5bd9ec119fd1499382387c4a41120d78
192 N12a0cc2f16064667af9fcca88232e5ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Bone and Bones
194 rdf:type schema:DefinedTerm
195 N15601c5d97ef47a7bde5325ffeedcff7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Osteoporosis
197 rdf:type schema:DefinedTerm
198 N1676458b4c574d75937a012a1813546b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Female
200 rdf:type schema:DefinedTerm
201 N17acec2d48264131a26dd8435de0c052 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Factor Xa Inhibitors
203 rdf:type schema:DefinedTerm
204 N1d6e9fb26e80452bab23cbeb39a0c51d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Atrial Fibrillation
206 rdf:type schema:DefinedTerm
207 N29e9df9b2bae44fc8578e1e331e62523 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Pilot Projects
209 rdf:type schema:DefinedTerm
210 N36c9dffd140648b486ad26b281c4e876 rdf:first sg:person.0744472011.56
211 rdf:rest rdf:nil
212 N47e7d080323b4602aa9e5a2dd92edd03 rdf:first sg:person.01002676641.46
213 rdf:rest N711df0fef152482497bb0a1e2ea41824
214 N5536a71fcdd3419e921e1d0b756ebdd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Prospective Studies
216 rdf:type schema:DefinedTerm
217 N58c79c372797460ea477478a93f83882 rdf:first sg:person.01222621771.41
218 rdf:rest N8949eb5f40444ff29113ea89ba855413
219 N5bd9ec119fd1499382387c4a41120d78 rdf:first sg:person.010156707735.27
220 rdf:rest Nd0c8cd1f5b3245309453eedb7df3ecc7
221 N67ba1974a6634a4695f2e878945ffff0 schema:name doi
222 schema:value 10.1007/s00380-017-0950-2
223 rdf:type schema:PropertyValue
224 N6d983daebffd4fb1bd5db8dfeb633e3f schema:volumeNumber 32
225 rdf:type schema:PublicationVolume
226 N711df0fef152482497bb0a1e2ea41824 rdf:first sg:person.016506421751.89
227 rdf:rest Nc0cc2ec3814340ea9b96ca3fb1444dcd
228 N84a32854a8664118a15fb7fa9c519892 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Humans
230 rdf:type schema:DefinedTerm
231 N8949eb5f40444ff29113ea89ba855413 rdf:first sg:person.0641672710.88
232 rdf:rest Ne36789c32e184e8a9055e320a7ffa61c
233 N91de79e4cf1e409e92933f5dacfc1ce9 schema:issueNumber 8
234 rdf:type schema:PublicationIssue
235 N9a36bb4927854717919243a30b498b3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Drug Substitution
237 rdf:type schema:DefinedTerm
238 N9f84146413fe4f90af409b601934b852 schema:name Springer Nature - SN SciGraph project
239 rdf:type schema:Organization
240 Na1a2c4a315d445c9ad811f97b431ba57 rdf:first sg:person.01105601162.18
241 rdf:rest N47e7d080323b4602aa9e5a2dd92edd03
242 Na477a870e93a44db9228ca513f393e53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name Japan
244 rdf:type schema:DefinedTerm
245 Na59b53eaa21142c48e58df9917af43cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
246 schema:name Cytokines
247 rdf:type schema:DefinedTerm
248 Nb184f93b6a1b4aae9cfec8a0e524acf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
249 schema:name Aged
250 rdf:type schema:DefinedTerm
251 Nb1dd233a943647f9b96b13b88ab060ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
252 schema:name Pulse Wave Analysis
253 rdf:type schema:DefinedTerm
254 Nb9c9303af26e49a3b326f0dca5d145ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
255 schema:name Survival Rate
256 rdf:type schema:DefinedTerm
257 Nbe962c7d3ce0441f8050053955da8b1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
258 schema:name Stroke
259 rdf:type schema:DefinedTerm
260 Nc0cc2ec3814340ea9b96ca3fb1444dcd rdf:first sg:person.01116550365.77
261 rdf:rest Nce650f5a4bf24d118dc45eb0c83e4f88
262 Nc23e4b0aee6040c490490ce64a0bb372 rdf:first sg:person.01342560525.52
263 rdf:rest N10909f4d2ca245fca1c768a49abbafea
264 Nce650f5a4bf24d118dc45eb0c83e4f88 rdf:first sg:person.01220560516.45
265 rdf:rest N36c9dffd140648b486ad26b281c4e876
266 Nd0c8cd1f5b3245309453eedb7df3ecc7 rdf:first sg:person.010754270335.39
267 rdf:rest N58c79c372797460ea477478a93f83882
268 Nd358d829bf434d29a2c502566b7b8839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
269 schema:name Incidence
270 rdf:type schema:DefinedTerm
271 Nd47fffd662dd40bbbe8c5eaa700fb15c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
272 schema:name Rivaroxaban
273 rdf:type schema:DefinedTerm
274 Nd94a91a6dca443cc9a1521f9ccfdb4be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
275 schema:name Vascular Stiffness
276 rdf:type schema:DefinedTerm
277 Nd96d6881d3ce4f63b681805102863da5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
278 schema:name Anticoagulants
279 rdf:type schema:DefinedTerm
280 Nd998f491af5546f0931bceeda2e67e55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
281 schema:name Warfarin
282 rdf:type schema:DefinedTerm
283 Ne0f383703b1c42c3a007d89cab3374a5 schema:name dimensions_id
284 schema:value pub.1083862484
285 rdf:type schema:PropertyValue
286 Ne36789c32e184e8a9055e320a7ffa61c rdf:first sg:person.01023151240.06
287 rdf:rest Na1a2c4a315d445c9ad811f97b431ba57
288 Ne85b54e5565e4cc3a613db930e1c4192 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
289 schema:name Biomarkers
290 rdf:type schema:DefinedTerm
291 Ne89acbf0cf5d40a5979cee56465ce75c schema:name pubmed_id
292 schema:value 28233091
293 rdf:type schema:PropertyValue
294 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
295 schema:name Medical and Health Sciences
296 rdf:type schema:DefinedTerm
297 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
298 schema:name Cardiorespiratory Medicine and Haematology
299 rdf:type schema:DefinedTerm
300 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
301 schema:name Clinical Sciences
302 rdf:type schema:DefinedTerm
303 sg:journal.1095887 schema:issn 0910-8327
304 1615-2573
305 schema:name Heart and Vessels
306 schema:publisher Springer Nature
307 rdf:type schema:Periodical
308 sg:person.01002676641.46 schema:affiliation grid-institutes:grid.410786.c
309 schema:familyName Kameda
310 schema:givenName Ryo
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002676641.46
312 rdf:type schema:Person
313 sg:person.010156707735.27 schema:affiliation grid-institutes:grid.410786.c
314 schema:familyName Kakizaki
315 schema:givenName Ryota
316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010156707735.27
317 rdf:type schema:Person
318 sg:person.01023151240.06 schema:affiliation grid-institutes:grid.410786.c
319 schema:familyName Kitasato
320 schema:givenName Lisa
321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023151240.06
322 rdf:type schema:Person
323 sg:person.010754270335.39 schema:affiliation grid-institutes:grid.410786.c
324 schema:familyName Nemoto
325 schema:givenName Teruyoshi
326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010754270335.39
327 rdf:type schema:Person
328 sg:person.01105601162.18 schema:affiliation grid-institutes:grid.410786.c
329 schema:familyName Hashimoto
330 schema:givenName Takuya
331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105601162.18
332 rdf:type schema:Person
333 sg:person.01116550365.77 schema:affiliation grid-institutes:grid.410786.c
334 schema:familyName Shimohama
335 schema:givenName Takao
336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116550365.77
337 rdf:type schema:Person
338 sg:person.01220560516.45 schema:affiliation grid-institutes:grid.410786.c
339 schema:familyName Tojo
340 schema:givenName Taiki
341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220560516.45
342 rdf:type schema:Person
343 sg:person.01222621771.41 schema:affiliation grid-institutes:grid.410786.c
344 schema:familyName Fujiyoshi
345 schema:givenName Kazuhiro
346 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222621771.41
347 rdf:type schema:Person
348 sg:person.01342560525.52 schema:affiliation grid-institutes:grid.410786.c
349 schema:familyName Namba
350 schema:givenName Sayaka
351 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342560525.52
352 rdf:type schema:Person
353 sg:person.016506421751.89 schema:affiliation grid-institutes:grid.410786.c
354 schema:familyName Meguro
355 schema:givenName Kentaro
356 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016506421751.89
357 rdf:type schema:Person
358 sg:person.0630073565.16 schema:affiliation grid-institutes:grid.410786.c
359 schema:familyName Yamaoka-Tojo
360 schema:givenName Minako
361 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630073565.16
362 rdf:type schema:Person
363 sg:person.0641672710.88 schema:affiliation grid-institutes:grid.410786.c
364 schema:familyName Hashikata
365 schema:givenName Takehiro
366 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641672710.88
367 rdf:type schema:Person
368 sg:person.0744472011.56 schema:affiliation grid-institutes:grid.410786.c
369 schema:familyName Ako
370 schema:givenName Junya
371 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744472011.56
372 rdf:type schema:Person
373 sg:pub.10.1007/s00125-014-3348-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1008902979
374 https://doi.org/10.1007/s00125-014-3348-z
375 rdf:type schema:CreativeWork
376 sg:pub.10.1007/s00380-014-0496-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043676979
377 https://doi.org/10.1007/s00380-014-0496-5
378 rdf:type schema:CreativeWork
379 sg:pub.10.1007/s00380-016-0868-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004414565
380 https://doi.org/10.1007/s00380-016-0868-0
381 rdf:type schema:CreativeWork
382 sg:pub.10.1007/s00774-009-0094-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017555813
383 https://doi.org/10.1007/s00774-009-0094-2
384 rdf:type schema:CreativeWork
385 sg:pub.10.1007/s00774-013-0490-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004167978
386 https://doi.org/10.1007/s00774-013-0490-5
387 rdf:type schema:CreativeWork
388 sg:pub.10.1038/ijir.2014.14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025583726
389 https://doi.org/10.1038/ijir.2014.14
390 rdf:type schema:CreativeWork
391 sg:pub.10.2119/molmed.2009.00052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068965203
392 https://doi.org/10.2119/molmed.2009.00052
393 rdf:type schema:CreativeWork
394 grid-institutes:grid.410786.c schema:alternateName Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
395 Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, 252-0373, Sagamihara, Japan
396 schema:name Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
397 Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, 252-0373, Sagamihara, Japan
398 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...